Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Condition(s):Myasthenic Syndromes, CongenitalLast Updated:April 2, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Myasthenic Syndromes, CongenitalLast Updated:April 2, 2021Completed
Condition(s):Myasthenic Syndromes, CongenitalLast Updated:October 10, 2007Unknown status
Condition(s):Congenital Myasthenic SyndromeLast Updated:June 2, 2023No longer available
Condition(s):Congenital Myasthenic SyndromeLast Updated:February 23, 2024Recruiting
Condition(s):Congenital Myasthenic SyndromeLast Updated:January 1, 2016Completed
Condition(s):Myasthenic Syndromes, CongenitalLast Updated:January 5, 2024No longer available
Condition(s):Lambert-Eaton Myasthenic Syndrome; Congenital Myasthenic SyndromeLast Updated:April 11, 2022Approved for marketing
Condition(s):Lambert-Eaton Myasthenic Syndrome (LEMS); Congenital Myasthenia (CM)Last Updated:December 11, 2019No longer available
Condition(s):Congenital Myasthenic Syndrome; Lambert-Eaton Myasthenic Syndrome; Nystagmus, AcquiredLast Updated:September 13, 2023No longer available
Condition(s):Congenital Myasthenic SyndromeLast Updated:November 18, 2011Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.